733 related articles for article (PubMed ID: 30996060)
1. Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study.
Lipton RB; Tepper SJ; Reuter U; Silberstein S; Stewart WF; Nilsen J; Leonardi DK; Desai P; Cheng S; Mikol DD; Lenz R
Neurology; 2019 May; 92(19):e2250-e2260. PubMed ID: 30996060
[TBL] [Abstract][Full Text] [Related]
2. Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab.
Buse DC; Lipton RB; Hallström Y; Reuter U; Tepper SJ; Zhang F; Sapra S; Picard H; Mikol DD; Lenz RA
Cephalalgia; 2018 Sep; 38(10):1622-1631. PubMed ID: 30086681
[TBL] [Abstract][Full Text] [Related]
3. Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial.
Tepper SJ; Diener HC; Ashina M; Brandes JL; Friedman DI; Reuter U; Cheng S; Nilsen J; Leonardi DK; Lenz RA; Mikol DD
Neurology; 2019 May; 92(20):e2309-e2320. PubMed ID: 30996056
[TBL] [Abstract][Full Text] [Related]
4. A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults.
Sakai F; Takeshima T; Tatsuoka Y; Hirata K; Lenz R; Wang Y; Cheng S; Hirama T; Mikol DD
Headache; 2019 Nov; 59(10):1731-1742. PubMed ID: 31612482
[TBL] [Abstract][Full Text] [Related]
5. Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study.
Ashina M; Dodick D; Goadsby PJ; Reuter U; Silberstein S; Zhang F; Gage JR; Cheng S; Mikol DD; Lenz RA
Neurology; 2017 Sep; 89(12):1237-1243. PubMed ID: 28835404
[TBL] [Abstract][Full Text] [Related]
6. Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine.
Ford JH; Kurth T; Starling AJ; Ayer DW; Wietecha LA; Port MD; Rettiganti M; Ruff DD
Headache; 2020 Nov; 60(10):2304-2319. PubMed ID: 33249580
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
Reuter U; Goadsby PJ; Lanteri-Minet M; Wen S; Hours-Zesiger P; Ferrari MD; Klatt J
Lancet; 2018 Nov; 392(10161):2280-2287. PubMed ID: 30360965
[TBL] [Abstract][Full Text] [Related]
8. Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study.
Takeshima T; Sakai F; Hirata K; Imai N; Matsumori Y; Yoshida R; Peng C; Cheng S; Mikol DD
Headache; 2021 Jun; 61(6):927-935. PubMed ID: 34153117
[TBL] [Abstract][Full Text] [Related]
9. Measures of Functioning in Patients With Episodic Migraine: Findings From a Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial With Galcanezumab.
Ayer DW; Skljarevski V; Ford JH; Nyhuis AW; Lipton RB; Aurora SK
Headache; 2018 Sep; 58(8):1225-1235. PubMed ID: 30106172
[TBL] [Abstract][Full Text] [Related]
10. Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial.
Lipton RB; Pozo-Rosich P; Blumenfeld AM; Li Y; Severt L; Stokes JT; Creutz L; Gandhi P; Dodick D
Neurology; 2023 Feb; 100(8):e764-e777. PubMed ID: 36396451
[TBL] [Abstract][Full Text] [Related]
11. Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN).
Ford J; Tassorelli C; Leroux E; Wang S; Ayer D; Nichols R; Detke H
Qual Life Res; 2021 Jan; 30(1):105-115. PubMed ID: 32930994
[TBL] [Abstract][Full Text] [Related]
12. Medium-term real-world data for erenumab in 177 treatment resistant or difficult to treat chronic migraine patients: persistence and patient reported outcome measures after 17-30 months.
Troy E; Shrukalla AA; Buture A; Conaty K; Macken E; Lonergan R; Melling J; Long N; Shaikh E; Birrane K; Tomkins EM; Goadsby PJ; Ruttledge MH
J Headache Pain; 2023 Jan; 24(1):5. PubMed ID: 36647006
[TBL] [Abstract][Full Text] [Related]
13. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine.
Dodick DW; Ashina M; Brandes JL; Kudrow D; Lanteri-Minet M; Osipova V; Palmer K; Picard H; Mikol DD; Lenz RA
Cephalalgia; 2018 May; 38(6):1026-1037. PubMed ID: 29471679
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of erenumab in women with a history of menstrual migraine.
Pavlovic JM; Paemeleire K; Göbel H; Bonner J; Rapoport A; Kagan R; Zhang F; Picard H; Mikol DD
J Headache Pain; 2020 Aug; 21(1):95. PubMed ID: 32746775
[TBL] [Abstract][Full Text] [Related]
15. A Controlled Trial of Erenumab for Episodic Migraine.
Goadsby PJ; Reuter U; Hallström Y; Broessner G; Bonner JH; Zhang F; Sapra S; Picard H; Mikol DD; Lenz RA
N Engl J Med; 2017 Nov; 377(22):2123-2132. PubMed ID: 29171821
[TBL] [Abstract][Full Text] [Related]
16. A prospective real-world analysis of erenumab in refractory chronic migraine.
Lambru G; Hill B; Murphy M; Tylova I; Andreou AP
J Headache Pain; 2020 Jun; 21(1):61. PubMed ID: 32487102
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.
Tepper S; Ashina M; Reuter U; Brandes JL; Doležil D; Silberstein S; Winner P; Leonardi D; Mikol D; Lenz R
Lancet Neurol; 2017 Jun; 16(6):425-434. PubMed ID: 28460892
[TBL] [Abstract][Full Text] [Related]
18. Timing and durability of response to erenumab in patients with episodic migraine.
McAllister PJ; Turner I; Reuter U; Wang A; Scanlon J; Klatt J; Chou DE; Paiva da Silva Lima G
Headache; 2021 Nov; 61(10):1553-1561. PubMed ID: 34841526
[TBL] [Abstract][Full Text] [Related]
19. Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraine.
Popoff E; Johnston K; Croop R; Thiry A; Harris L; Powell L; Coric V; L'Italien G; Moren J
Headache; 2021 Jun; 61(6):906-915. PubMed ID: 34021585
[TBL] [Abstract][Full Text] [Related]
20. Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience.
Russo A; Silvestro M; Scotto di Clemente F; Trojsi F; Bisecco A; Bonavita S; Tessitore A; Tedeschi G
J Headache Pain; 2020 Jun; 21(1):69. PubMed ID: 32517693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
